Would monitoring CMV immune responses allow improved control of CMV in stem cell transplant patients

Journal of Clinical Virology

Volumn 35, Issue 4, 2006, Pages 493-495

  Ljungman, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CMV; Immune response; Preemptive therapy; Virological monitoring

Indexed keywords

ANTIVIRUS AGENT;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; INFECTION RISK; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; TOXICITY; VIRUS LOAD; VIRUS RESISTANCE;

EID: 33644653601     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2005.10.017     Document Type: Article

References (20)

1. R.K. Avery, K.A. Adal, D.L. Longworth, and B.J. Bolwell A survey of allogeneic bone marrow transplant programs in the United States regarding cytomegalovirus prophylaxis and preemptive therapy Bone Marrow Transplant 26 2000 763 767
2. M. Boeckh, R.A. Bowden, T. Gooley, D. Myerson, and L. Corey Successful modification of a pp65 antigenemia-based early treatment strategy for prevention of cytomegalovirus disease in allogeneic marrow transplant recipients [letter] Blood 93 1999 1781 1782
3. M. Boeckh, T.A. Gooley, D. Myerson, T. Cunningham, G. Schoch, and R.A. Bowden Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study Blood 88 1996 4063 4071
4. M. Boeckh, W. Leisenring, S.R. Riddell, R.A. Bowden, M.L. Huang, and D. Myerson Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity Blood 101 2003 407 414
5. K. Cwynarski, J. Ainsworth, M. Cobbold, S. Wagner, P. Mahendra, and J. Apperley Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation Blood 97 2001 1232 1240
6. H. Einsele, G. Ehninger, H. Hebart, K.M. Wittkowski, U. Schuler, and G. Jahn Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation Blood 86 1995 2815 2820
7. V.C. Emery, C.A. Sabin, A.V. Cope, D. Gor, A.F. Hassan-Walker, and P.D. Griffiths Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation Lancet 355 2000 2032 2036
8. G. Gerna, D. Lilleri, F. Baldanti, M. Torsellini, G. Giorgiani, and M. Zecca Human cytomegalovirus immediate-early mRNAemia versus pp65 antigenemia for guiding preemptive therapy in children and young adults undergoing hematopoietic stem cell transplantation: a prospective, randomized, open-label trial Blood 101 2003 5053 5060
9. J.M. Goodrich, M. Mori, C.A. Gleaves, C. Du Mond, M. Cays, and D.F. Ebeling Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation N Engl J Med 325 1991 1601 1607
10. H. Hebart, S. Daginik, S. Stevanovic, U. Grigoleit, A. Dobler, and M. Baur Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation Blood 99 2002 3830 3837
11. H. Hebart, P. Ljungman, T. Klingebiel, J. Loeffler, I. Lewensohhn-Fuchs, and L. Barkholt Prospective comparison of PCR-based versus late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allogeneic stem cell transplantation Blood 102 2003 195a
12. A. Humar, C. Paya, M.D. Pescovitz, E. Dominguez, K. Washburn, and E. Blumberg Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients Am J Transplant 4 2004 644 649
13. C. Junghanss, M. Boeckh, R.A. Carter, B.M. Sandmaier, M.B. Maris, and D.G. Maloney Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood 99 2002 1978 1985
14. P. Ljungman, J. Aschan, J.N. Azinge, L. Brandt, A. Ehrnst, and V. Hammarstrom Cytomegalovirus viraemia and specific T-helper cell responses as predictors of disease after allogeneic marrow transplantation Br J Haematol 83 1993 118 124
15. P. Ljungman, J. Aschan, I. Lewensohn-Fuchs, S. Carlens, K. Larsson, and B. Lönnqvist Results of different strategies for reducing cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients Transplantation 66 1998 1330 1334
16. P. Ljungman, R. De Bock, C. Cordonnier, H. Einsele, D. Engelhard, and J. Grundy Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT Bone Marrow Transplant 12 1993 399 403
17. F.M. Mattes, E.G. Hainsworth, A.M. Geretti, G. Nebbia, G. Prentice, and M. Potter A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients J Infect Dis 189 2004 1355 1361
18. W.G. Nichols, L. Corey, T. Gooley, W.L. Drew, R. Miner, and M. Huang Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes Blood 97 2001 867 874
19. E. Ozdemir, L.S. St John, G. Gillespie, S. Rowland-Jones, R.E. Champlin, and J.J. Molldrem Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells Blood 100 2002 3690 3697
20. N. Singh, C. Wannstedt, L. Keyes, T. Gayowski, M.M. Wagener, and T.V. Cacciarelli Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease Transplantation 79 2005 85 90